Get the Stockscreener App
11.02
6.69%
-0.79
Lyell Immunopharma Inc stock is traded at $11.02, with a volume of 19,787.
It is down -6.69% in the last 24 hours and up +16.92% over the past month.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
See More
Previous Close:
$11.81
Open:
$11.57
24h Volume:
19,787
Relative Volume:
0.15
Market Cap:
$163.19M
Revenue:
$54,000
Net Income/Loss:
$-210.26M
P/E Ratio:
-13.95
EPS:
-0.79
Net Cash Flow:
$-159.01M
1W Performance:
-11.27%
1M Performance:
+16.92%
6M Performance:
-6.66%
1Y Performance:
-63.27%
1-Day Range:
$11.02
$11.66
1-Week Range:
$11.02
$14.18
52-Week Range:
$7.65
$32.40
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Name
Lyell Immunopharma Inc
Sector
Industry
Phone
650 695-0677
Address
201 HASKINS WAY, SOUTH SAN FRANCISCO
Compare LYEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
11.02 | 219.48M | 54,000 | -210.26M | -159.01M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-30-24 | Downgrade | BofA Securities | Buy → Underperform |
| Jun-27-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-11-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-17-22 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | BofA Securities | Buy |
| Jul-12-21 | Initiated | Goldman | Buy |
| Jul-12-21 | Initiated | JP Morgan | Overweight |
| Jul-12-21 | Initiated | Morgan Stanley | Overweight |
View All
Lyell Immunopharma Inc Stock (LYEL) Latest News
Why Lyell Immunopharma Inc. stock attracts strong analyst attentionSecure Buy Strategy Based on Risk Parameters - Newser
Visual trend scoring systems applied to Lyell Immunopharma Inc.Buy Alert Based on RSI and Volume - Newser
Is Lyell Immunopharma Inc. a growth stock or a value stockStock Market Picks With High Returns - jammulinksnews.com
Should I hold or sell Lyell Immunopharma Inc. stock in 2025Daily Trading Picks Backed By Experts - jammulinksnews.com
Analyzing drawdowns of Lyell Immunopharma Inc. with statistical toolsEarnings Impact and Stock Reaction Analysis - Newser
Can you recover from losses in Lyell Immunopharma Inc.Free Trade Timing Strategy With Technical Data - Newser
Does Lyell Immunopharma Inc. show high probability of reboundPortfolio Positioning Strategy With Timing - Newser
How to use a screener to detect Lyell Immunopharma Inc. breakoutsPrice Spike Prediction for Active Traders - Newser
Does Lyell Immunopharma Inc. stock perform well during market downturnsMarket Forecast Picks That Work - jammulinksnews.com
When is Lyell Immunopharma Inc. stock expected to show significant growthPre Market Insights For Beginners - jammulinksnews.com
Detecting price anomalies in Lyell Immunopharma Inc. with AIFree Weekly Chart Analysis With Entry Advice - Newser
Should you wait for a breakout in Lyell Immunopharma Inc.Swing Trade Signal and Price Prediction - Newser
Live Chart Scan Detects Wedge Pattern in Lyell Immunopharma Inc.Entry and Exit Strategy Optimizer Tool Tested - metal.it
Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments - The Community Press
Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments - Benzinga
Lyell Immunopharma Inc. Stock Flags Risk Zone in Volatility IndexSmart Allocation Stock Pick Insights Gaining Interest - metal.it
Buy Signal for Lyell Immunopharma Inc. Stock Key Technical Indicators to WatchAlgorithmic Forecast for Swing Trading Picks - Newser
Published on: 2025-07-29 03:38:25 - Newser
What is the dividend policy of Lyell Immunopharma Inc. stockAchieve rapid portfolio growth with expert guidance - jammulinksnews.com
How to use a screener to detect Lyell Immunopharma Inc. breakouts Free Technical Entry Strategy for Beginners - Newser
How volatile is Lyell Immunopharma Inc. stock compared to the marketInvest confidently with expert support - jammulinksnews.com
What catalysts could drive Lyell Immunopharma Inc. stock higher in 2025Extraordinary profit generation - jammulinksnews.com
Sectors Driving Future Growth for Lyell Immunopharma Inc. StockHigh Potential Safe Trades - Newser
What makes Lyell Immunopharma Inc. stock price move sharplyElite Investor Club - Newser
What drives Lyell Immunopharma Inc. stock priceExceptional financial outcomes - PrintWeekIndia
Lyell Immunopharma $100M Deal: Can Buyers Hold the Stock After 20% Surge? - FXLeaders
Lyell Immunopharma $100M Deal: Can Buyers Extend the Stock After 20% Surge? - FXLeaders
Lyell Immunopharma (LYEL) Stock Soars Following Private Placement Announcement - FinancialBuzz.com
Lyell Immunopharma's $100M Private Placement: How Milestone-Driven Capital Raises De-Risk Biotechs and Create Asymmetric Upside - AInvest
What makes Lyell Immunopharma Inc. stock attractive to long term investorsExplosive capital appreciation - jammulinksnews.com
Lyell Immunopharma announces up to $100M equity private placement - TipRanks
Everest Medicines raises $200M; Epirium Bio targets $55M Series B - Endpoints News
Lyell Immunopharma Taps Investors For $100 Million In New Funding - Finimize
Is Lyell Immunopharma Inc. a good long term investmentBreakthrough profits - PrintWeekIndia
Lyell Immunopharma secures up to $100 million in private placement - Investing.com
Lyell Immunopharma secures up to $100 million in private placement By Investing.com - Investing.com Nigeria
Lyell Immunopharma Secures $100 Million in Private Placement - TipRanks
Lyell Immunopharma Announces up to $100 Million Equity Private Placement - GlobeNewswire
Lyell Immunopharma Raises $100M to Advance Breakthrough Cancer Cell Therapy Through Pivotal Trials - Stock Titan
Is Lyell Immunopharma Inc. stock overhyped or has real potentialOutstanding capital returns - jammulinksnews.com
Lyell Immunopharma Inc Stock (LYEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):